Curated for Orthogate.org Members

EXECUTIVE SUMMARY

• Worldwide First: Biedermann Motech Further Expands MOSS!MODULARITY™ Platform with MOSS EOS® for Early Onset Scoliosis Surgery: Reported by Orthopedics This Week, Biedermann Motech initiated the selective international market introduction of the growth-friendly MOSS EOS® System featuring MOSS!MODULARITY™, allowing surgeons to implant headless screw shafts prior to attaching polyaxial tulip heads to maximize visualization and working room during complex pediatric deformity correction.
• NASS Issues Revised Clinical Coverage Recommendations Endorsing rhBMP-2 in High-Risk Adult Lumbar Spinal Fusion: Reported by Healio Orthopedics, the North American Spine Society (NASS) published updated clinical coverage guidance formally endorsing rhBMP-2 as an evidence-based osteoinductive adjunct in posterolateral lumbar fusion (PLF) and transforaminal lumbar interbody fusion (TLIF) for adult patients with established nonunion risk factors.
• Pacira Partners with Molteni Farmaceutici to Commercialize EXPAREL® Across the European Union and United Kingdom: Reported by Orthopedics This Week, Pacira BioSciences finalized an exclusive commercialization partnership with Molteni Farmaceutici to distribute EXPAREL® across key European markets and the UK ahead of a 2027 rollout, expanding non-opioid postsurgical pain management for joint arthroplasty and spine reconstruction.
• Zimmer OsseoFit Stemless Shoulder System Cleared: Zimmer, Inc. secured FDA 510(k) clearance (K262955) for the OsseoFit Stemless Shoulder System, indicated for stemless total shoulder arthroplasty in patients with glenohumeral osteoarthritis to optimize humeral bone preservation.
• Arthrex Beaming System Cleared: Arthrex, Inc. received FDA 510(k) clearance (K262975) for the Arthrex Beaming System, indicated for midfoot and hindfoot arthrodesis, Charcot neuroarthropathy reconstruction, and fracture fixation.

DAILY ANNOUNCEMENTS BY CATEGORY

Spine & Orthobiologics

Biedermann Motech — Worldwide First: Biedermann Motech Further Expands MOSS!MODULARITY™ Platform with MOSS EOS® for Early Onset Scoliosis Surgery

• Summary: Biedermann Motech announced the selective international market introduction of the MOSS EOS® System for the treatment of pediatric patients with severe early onset scoliosis (EOS). Incorporating the MOSS!MODULARITY™ platform, the growth-friendly spinal system enables surgeons to implant headless screw shafts prior to attaching polyaxial tulip heads in-situ or on the back-table.
• Key Details:
  • Device/System Name: MOSS EOS® System featuring MOSS!MODULARITY™
  • Status: Commercial Launch (Selective International Market Introduction)
  • Clinical Significance: Provides enhanced visualization and surgical working space during complex decompression, decortication, and osteotomy maneuvers without tulip head interference; allows customizable, staged posterior stabilization and individualized growth-preserving deformity correction in pediatric patients.
• Original Source: Orthopedics This Week

Corporate, M&A & Regulatory

North American Spine Society (NASS) — NASS Issues Revised Clinical Coverage Recommendations Endorsing rhBMP-2 in High-Risk Adult Lumbar Spinal Fusion

• Summary: The North American Spine Society (NASS) released revised coverage recommendations updating clinical indications for recombinant human bone morphogenetic protein-2 (rhBMP-2) in adult spinal arthrodesis. The updated guidance formally supports rhBMP-2 as an evidence-based adjunct in posterolateral lumbar fusion (PLF) and transforaminal lumbar interbody fusion (TLIF) specifically in adult patients with established risk factors for nonunion.
• Key Details:
  • Device/System Name: Recombinant Human Bone Morphogenetic Protein-2 (rhBMP-2) Coverage Recommendations
  • Status: Clinical Coverage Policy Guideline Revision
  • Clinical Significance: Clarifies evidence-based reimbursement criteria and reduces payer denial barriers for orthobiologic osteoinductive augmentation in high-risk spine surgery patients (such as multilevel fusions, revision arthrodesis, and metabolic bone disease) to mitigate pseudarthrosis and reoperation rates.
• Original Source: Healio Orthopedics

Corporate, M&A & Regulatory

Pacira BioSciences, Inc. — Pacira Partners with Molteni Farmaceutici to Commercialize EXPAREL® Across the European Union and United Kingdom

• Summary: Pacira BioSciences entered into an exclusive commercialization partnership with Molteni Farmaceutici to distribute and commercialize EXPAREL® across key European markets, including Italy, Germany, Austria, and Poland, with planned expansion to Switzerland and the UK. Under the agreement, Pacira manufactures the long-acting local analgesic while Molteni oversees regional regulatory, market access, and commercial execution, with commercial rollout scheduled for 2027.
• Key Details:
  • Device/System Name: EXPAREL® (bupivacaine liposome injectable suspension)
  • Status: Commercial Partnership & Exclusive Distribution Agreement
  • Clinical Significance: Accelerates international adoption of non-opioid, multiday postsurgical regional analgesia across inpatient and ambulatory orthopaedic surgery, advancing Enhanced Recovery After Surgery (ERAS) protocols and reducing perioperative opioid dependence in major joint arthroplasty and spine reconstruction.
• Original Source: Orthopedics This Week

RECENTLY INDEXED FDA 510(k) & PMA CLEARANCES — ORTHOPAEDIC

Note: The openFDA database typically indexes clearances 2–4 weeks after the official decision date. Dates shown reflect the FDA decision date, not the indexing date.